|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table I.** Effect of treatment during the enteral stage of the infection🞑 on the host intestinal parasite burden and *T. spiralis* female fecundity | | | | |
|  | **CBi/L** | | **CBi+** | |
|  | **Males** | **Females** | **Males** | **Females** |
| Variable  Treatment | **nAP\*** | | | |
| **Control** | 6.5 (2-17)a | 2.0 (0-5)a | 13.5 (9-19)a | 22.0 (10-27)a |
| **ABZ** | 7.0 (3-8)a | 1.5 (0-3)a | 13.5 (10-17)a | 8.0 (3-17)a |
| **S4A** | 6.5 (1-8)a | 2.0 (0-10)a | 19.5 (13-24)a | 17.0 (14-20)a |
| **S10A** | 7.0 (3-14)a | 0 (0-3)a | 15.0 (5-23)a | 21.0 (20-23)a |
| Variable  Treatment | **Ff#** | | | |
| **Control** | 29 ± 15.2 | 34⧫ | 50 ± 25.0 | 46 ± 16.6 |
| **ABZ** | --- | --- | --- | --- |
| **S4A** | --- | --- | --- | --- |
| **S10A** | --- | --- | --- | --- |
| 🞑Mice were treated on days 5, 6, and 7 p-i and sacrificed two days after the administration of the last dose (9 days p-i).  **nAP**: total number of intestinal adult parasites **Ff**: *T. spiralis* female fecundity  \*median (range) #mean ± SEM ⧫only one female recovered  nAP differences among treatments within genotype and sex were evaluated with the nonparametric Kruskal-Wallis test followed by Dunn’s test for between-groups comparison (nAP).  For each column, differences between groups not sharing the same superscript are significant at the 0.05 level. | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table II.** Effect of treatment during the enteral stage of the infection🞑 on the number of *T. spiralis* encysted L1 larvae. | | | | | | | | | | |
|  | **CBi/L** | | | |  | | **CBi+** | | | |
|  | **Males** | | **Females** | |  | | **Males** | | **Females** | |
| Variable  Treatment | **rLL\*#** | | | | | | | | | |
| **Control** | | 247 ± 97.1a | | 250 ± 54.2a | |  | | 1132 ± 221.7a | | 1463 ± 672.0a | |
| **ABZ** | | 20 ± 10.1b | | 27 ± 6.4b | |  | | 83 ± 28.0b | | 117 ± 42.9b | |
| **S4A** | | 12 ± 9.5b | | 9 ± 4.2b | |  | | 66 ± 10.2b | | 189 ± 117.2b | |
| **S10A** | | 19 ± 13.7b | | 16 ± 6.8b | |  | | 225 ± 119b | | 232 ± 76.7b | |
| 🞑Mice were treated on days 5, 6, and 7 p-i and sacrificed on day 37 p-i.  **\*rLL**: relative Larval Load, total number of encysted larvae per g of fresh tissue  #mean ± SEM  Differences among treatments within genotype and sex were evaluated by a one-way ANOVA, using Bonferroni’s post-test for comparisons between groups.  For each column, differences between groups not sharing the same superscript are significant at the 0.01 level. | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table III.** Effect of treatment during the migratory stage of the infection🞑 on the number of *T. spiralis* encysted L1 larvae. | | | | | | | | | | |
|  | **CBi/L** | | | |  | | **CBi+** | | | |
|  | **Males** | | **Females** | |  | | **Males** | | **Females** | |
| Variable  Treatment | **rLL\*#** | | | | | | | | | |
| **Control** | | 258 ± 76.7a | | 197 ± 33.9a | |  | | 1268 ± 462.4a | | 1168 ± 287.5a | |
| **ABZ** | | 159 ± 36.2a | | 151 ± 37.7a | |  | | 1107 ± 300.1a | | 1081 ± 287.7a | |
| **S4A** | | 113 ± 47.8a | | 142 ± 30.9a | |  | | 669 ± 499.5a | | 1596 ± 476.2a | |
| **S10A** | | 137 ± 42.9a | | 141 ± 31.2a | |  | | 669 ± 118.0a | | 869 ± 206.2a | |
| 🞑Mice were treated on days 13, 14, and 15 p-i and sacrificed on day 37 p-i.  **\*rLL**: relative Larval Load, total number of encysted larvae per g of fresh tissue  #mean ± SEM  Differences among treatments within genotype and sex were evaluated by a one-way ANOVA, using Bonferroni’s post-test for comparisons between groups.  For each column, differences between groups not sharing the same superscript are significant at the 0.05 level. | | | | | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table IV.** Effect of treatment during the chronic stage of infection🞑 on parasite muscle burden | | | | |
|  | **CBi/L** | | **CBi+** | |
|  | **Males** | **Females** | **Males** | **Females** |
| Variable  Treatment | **RLL\*#** | | | |
| **Control** | 240 ± 45.5a | 173 ± 75.5a | 998 ± 74.8a | 752 ± 157.9a |
| **ABZ** | 268 ± 71.6a | 283 ± 94.9a | 1084 ± 201.8a | 794 ± 144.9a |
| **S4A** | 266 ± 46.7a | 172 ± 45.7a | 1177 ± 154.8a | 662 ± 197.0a |
| **S10A** | 338 ± 57.6a | 130 ± 26.1a | 1172 ± 287.8a | 883 ± 210.9a |
| Variable  Treatment | **Proportion of dead *T. spiralis* muscle larvae (%)**⚫**⯎** | | | |
| **Control** | 20 (8-29)a | 9 (0-25)a | 24 (14-33)a | 7 (4-14)a |
| **ABZ** | 28 (0-37)a | 37 (0-68)a | 30 (15-60)a | 7 (5-21)a |
| **S4A** | 29 (14-37)a | 33 (0-96)a | 38 (7-93)a | 13 (6-20)a |
| **S10A** | 64 (18-88)b | 50 (6-100)a | 54 (13-74)a | 12 (5-22)a |
| 🞑Mice were treated on days 27, 28, and 29 p-i and were sacrificed on day 37 p-i.  **\*rLL**: relative larval load, total number of muscle encysted larvae per g of fresh tissue.  #mean ± SEM  Differences among treatments within genotype and sex were evaluated with the nonparametric Kruskal-Wallis test followed by Dunn’s test for between-groups comparison.  ⚫Percentage of dead muscle encysted larvae.  **⯎**median (range)  Differences among groups, within genotype and sex, were evaluated with the non-parametric Kruskal-Wallis test, using Dunn’s test for comparisons between groups.  For each variable, within column, groups not sharing the same superscript differ significantly (P<0.05). | | | | |